Search | Clinical Trials Finder

Conditions: Leukemia
Interventions: filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 15 Years to 69 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Paterson, New Jersey

Conditions: Breast Cancer Female
Interventions: Tamoxifen, Letrozole, Anastrozole, or Exemestane; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 65 Years and older · Female only
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 6
States / cities: New Haven, Connecticut • Charlottesville, Virginia • Culpeper, Virginia + 3 more

Conditions: Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pain therapy, radiofrequency ablation; Procedure
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 21 Years to 120 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 8
States / cities: Birmingham, Alabama • Worcester, Massachusetts • St Louis, Missouri + 4 more

Conditions: Prostate Cancer
Interventions: docetaxel, mitoxantrone hydrochloride, conventional surgery; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions: Guanfacine (GFC), Cromolyn Sodium, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma
Interventions: BKM120, Surgery; Drug · Procedure
Lead sponsor: L. Nicolas Gonzalez Castro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Care Giver, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions: Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 7 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Failure
Interventions: Edwards APTURE transcatheter shunt system, Sham procedure; Device · Diagnostic Test
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 17
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 13 more

Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
Interventions: prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis; Drug · Other · Genetic
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • Stanford, California • Atlanta, Georgia + 6 more

Conditions: Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
Interventions: Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Computer-Assisted Cognitive Training, Questionnaire Administration, Standard Follow-Up Care; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Dietary Intervention, Medical Device Usage and Evaluation, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Breast Cancer
Interventions: Faslodex, Herceptin; Drug · Biological
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Redondo Beach, California • San Antonio, Texas

Conditions: Hematologic Malignancies
Interventions: L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine, Cyclophosphamide, Tacrolimus, Mesna, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Hematopoietic stem cell transplantation (HSCT); Drug · Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer Survivor, Healthy Subject, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer
Interventions: Educational Intervention, Internet-Based Intervention, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration; Other · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Degenerative Joint Disease, Osteoarthritis, Hip, Avascular Necrosis of Hip, Traumatic Arthropathy-Hip
Interventions: Hip Innovation Technology Reverse Hip Replacement System, Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.; Device
Lead sponsor: Hip Innovation Technology; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2038
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • Baltimore, Maryland + 2 more

Conditions: Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Incomplete Spinal Cord Injury
Interventions: EA-KAFO; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostate Cancer, Prostate Neoplasm
Interventions: HDR brachytherapy; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
Interventions: ofatumumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Recurrent Ovarian Carcinoma
Interventions: Behavioral Intervention, Electronic Health Record Review, Interview, Survey Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 62
States / cities: Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 50 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer
Interventions: stereotactic body radiation therapy, four fraction split-course SBRT; Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Head and Neck Cancer
Interventions: blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging, functional magnetic resonance imaging, intensity-modulated radiation therapy, radiation therapy treatment planning/simulation; Procedure · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

Radiofrequency Ablation in Treating Patients With Bone Metastases

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

PCRC-Supported Legacy Intervention in Pediatric Palliative Care

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin

Safety and Effectiveness of the HIT Reverse HRS

Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer